Evidence map›Paper›PMID 42679206›Full record

ArticleThe journal of physical chemistry letters2026

Multipathway Aggregation Drives Concentration-Dependent Amyloid Polymorphism and Time-Dependent Morphological Evolution.

Kamal Bhandari, Wuzhou Xiong, Tianyi Hou, Pu Chun Ke, Feng Ding

Abstract read
In one paragraph

Article in The journal of physical chemistry letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kamal BhandariDepartment of Physics and Astronomy, Clemson University, Clemson, South Carolina29634, United States.ORCID 0000-0001-5174-4729
Wuzhou XiongDepartment of Physics and Astronomy, Clemson University, Clemson, South Carolina29634, United States.
Tianyi HouDivision of Medicine, University College London, LondonWC1E 6BT, United Kingdom.
Pu Chun KeDrug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC3052, Australia.ORCID 0000-0003-2134-0859
Feng DingDepartment of Physics and Astronomy, Clemson University, Clemson, South Carolina29634, United States.ORCID 0000-0003-1850-6336

Funding

Tissue Structural and Neural Remodeling in Human Sacroiliac JointP20GM121342 · NIGMS · CLEMSON UNIVERSITY · PI Jeryl Jones · 2018 to 2026
$24.7M
Inhibition of Human Islet Amyloid Polypeptide AggregationR35GM145409 · NIGMS · CLEMSON UNIVERSITY · PI Feng Ding · 2022 to 2026
$2.0M
Clemson University 2349368NIGMS NIH HHS P20 GM121342NIGMS NIH HHS R35 GM145409NIGMS NIH HHS R35GM145409South Carolina Alzheimer?s Disease Research Center NA
6 · The paper itself

Abstract

Amyloid aggregation into polymorphic fibrils is central to many neurodegenerative and systemic diseases, yet the physical origins of fibril polymorphism and time-dependent morphological evolution remain unclear. Because mature fibril morphologies are separated by high energy barriers, direct interconversion is unlikely. Here, we propose a multipathway aggregation model in which oligomeric nuclei with distinct sizes and chemical potentials seed different fibril morphologies. The abundance and temporal evolution of these polymorphs are governed by pathway-specific fibrillization barriers and fibril stabilities, allowing kinetically favored morphologies to dominate early but to be replaced by more stable forms over time. Differences in nucleus size further introduce concentration dependence, biasing aggregation toward different intermediates and fibril morphologies at low versus high concentrations. This framework helps rationalize the substantial concentration disparity between in vitro experiments and in vivo environments and highlights the importance of considering multipathway, concentration-dependent aggregation in studying amyloidosis and designing antiamyloidosis strategies.

Indexed as

AmyloidKineticsProtein AggregatesTime FactorsAmyloidProtein Aggregates

Identifiers

PMID42679206
PMCPMC13591442

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.